CALT News and Press, Calliditas Therapeutics AB From 12/20/22

Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022 PR Newswire STOCKHOLM , Dec. 21, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO ...

Calliditas ( NASDAQ: CALT ) signed a licensing agreement with Viatris ( NASDAQ: VTRS ) to register and commercialize Nefecon in Japan for treating chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN). Under the agreement, Sweden-based Calliditas is en...

Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan PR Newswire Calliditas announces that it has entered into an agreement with Viatris to bring Nefecon®, a specialty therapy focused...

Calliditas to host fireside chat with its China commercial partner, Everest Medicines PR Newswire STOCKHOLM , Dec. 9, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a fireside chat with its commercial par...

Calliditas Therapeutics ( OTCPK:CLTEF ) ( NASDAQ: CALT ) said China's National Medical Products Administration (NMPA) accepted to review Everest Medicines' new drug application (NDA) for kidney disease drug Nefecon. Calliditas said that Nefecon, if approved, w...

Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA PR Newswire STOCKHOLM , Nov. 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today...

Calliditas Therapeutics press release ( NASDAQ: CALT ): Q3 GAAP EPS of SEK 0.21. Revenue of SEK 260.1M (+31.2% Y/Y). Cash amounted to SEK 736.2M and SEK 1,163.8M as of September 30, 2022 and 2021, respectively. "We expect to achieve net sales fr...

Calliditas Therapeutics: Interim Report Q3, 2022 PR Newswire Conditional Marketing Authorization in EU Granted for Kinpeygo ® STOCKHOLM , Nov. 14, 2022 /PRNewswire/ -- "On July 15th the European Commission issued the conditional ...

Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape PR Newswire STOCKHOLM , Nov. 7, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Le...

Calliditas Therapeutics' nomination committee composition for the AGM 2023 PR Newswire Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2023. STOCKHOLM , Oct. 21, 2022 /PRNewswire/ -- The nominatio...